HPV

New research reveals almost half of women in the U.S. 40 and older have not had a breast cancer screening since March 2020

Retrieved on: 
Thursday, September 29, 2022

Of these women, 57% have never had a breast cancer screening or have not had a breast cancer screening in six or more years, and 22% cite a lack of symptoms as the reason for not having the screening.

Key Points: 
  • Of these women, 57% have never had a breast cancer screening or have not had a breast cancer screening in six or more years, and 22% cite a lack of symptoms as the reason for not having the screening.
  • Women of average risk should begin breast cancer screenings at age 40 and continue to get screened annually.
  • Screenings can identify cancer before symptoms appear, said Jody Hoyos, president and chief operating officer of the Prevent Cancer Foundation.
  • 34% of women 40 and older do not know how often they should be screened for breast cancer.

Cervical Cancer Diagnostic Global Market Report 2022: Rising Prevalence of Cervical Cancer Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 28, 2022

The global cervical cancer diagnostics market size is expected to reach USD 9,180.63 Million in 2030 and register a revenue CAGR of 5.0% over the forecast period, according to latest report.

Key Points: 
  • The global cervical cancer diagnostics market size is expected to reach USD 9,180.63 Million in 2030 and register a revenue CAGR of 5.0% over the forecast period, according to latest report.
  • The growth of this market is driven by the rising prevalence of cervical cancer and government initiatives for early detection of cervical cancer.
  • According to the National Cancer Institute, in 2019, an estimated 13,170 women in the United States will be diagnosed with cervical cancer.
  • The diagnostic test used for cervical cancer is a simple process in which a sample of cervical tissue is taken and examined for the presence of cancer cells.

Asia Pacific Travel Vaccines Market Report 2022: Surge in Incidences of Infectious Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022

The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.

Key Points: 
  • The Asia Pacific travel vaccines market is expected to grow at a good CAGR during the forecast period.
  • The Asia Pacific travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • The Asia Pacific travel vaccines market, based on application, is segmented into domestic travel and outbound travel.
  • Based on country, the Asia Pacific travel vaccines market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific.

Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Retrieved on: 
Tuesday, September 27, 2022

VB10.2210 induced broad and strong T cell responses, dominated by killer CD8 T cells, against both Spike- and non-Spike antigens.

Key Points: 
  • VB10.2210 induced broad and strong T cell responses, dominated by killer CD8 T cells, against both Spike- and non-Spike antigens.
  • By contrast, VB10.2210 is designed to induce T cell responses against epitopes from seven additional antigens thatarehighly conserved across previous and existing SARS-CoV-2 variants.
  • The vaccine candidate VB10.2210 encodes both Spike- and non-Spike T cell epitopes, identified and validated by Adaptive Biotechnologies.
  • VB10.2210 is a T cell focused vaccine candidate, encoding 96 clinically validated T cell epitopes spanning a total of eight SARS-CoV-2 proteins, including Spike.

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

Retrieved on: 
Monday, September 26, 2022

The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzos position in the oncology market and paves the way for expansion into the growing spatial biology space.

Key Points: 
  • The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzos position in the oncology market and paves the way for expansion into the growing spatial biology space.
  • Enzos AMPIVIEW RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA ISH technology.
  • This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology.
  • In HPV testing, detecting the spatial localization of active HPV in tumor cells is critical in assessing its clinical significance, and the AMPIVIEW HPV RNA probes make this possible.

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

Parker Labs Partners with Tristel to Deliver Ultrasound Disinfectant for U.S. Market

Retrieved on: 
Thursday, September 22, 2022

FAIRFIELD, N.J., Sept. 22, 2022 /PRNewswire/ -- Parker Laboratories Inc. has entered a commercial partnership with UK-based infection prevention company Tristel to manufacture and distribute the company's disinfectant foams for U.S. markets. Under the exclusive agreement, Parker will manufacture and distribute Tristel DUO, a disinfecting foam approved for the cleaning and disinfection of general medical surfaces—including ultrasound transducers.

Key Points: 
  • Tristel DUO is an alcohol- and bleach-free cleaner and disinfectant that has been shown to be bactericidal, fungicidal, and virucidal.
  • Published scientific research concludes that Tristel DUO is successful in inactivating Human papillomavirus (HPV) type 16 and type 18.
  • Tristel DUO foam will not damage ultrasound transducers and can be used with any dry wipe, making it a convenient and economical solution for transducer disinfection.
  • Tristel DUO meets the requirements for disinfection of ultrasound transducers used in percutaneous procedures, as detailed in a recently published Intersocietal Position Statement .

Europe Travel Vaccines Market Analysis/Forecast Report 2021-2022 & 2028 Featuring Abbott, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi, & Valneva - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The "Europe Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.
  • The travel vaccines market in Europe is expected to grow from US$ 995.47 million in 2021 to US$ 1,885.56 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028.
  • Hepatitis, HIV/AIDS, human papillomavirus (HPV), meningococcal disease, typhoid, and yellow fever are among the various chronic diseases detected across the region.
  • The vaccine routine includes routine vaccines for review before traveling, vaccines for certain destinations, and vaccines demanded by certain countries.

Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx

Retrieved on: 
Monday, September 19, 2022

Naveris blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.

Key Points: 
  • Naveris blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.
  • Proceeds from this financing will be used to advance commercialization of NavDx, Naveris flagship blood test for the early detection of cancers caused by the human papillomavirus (HPV), and to generate the clinical data needed to expand into other cancer types and indications.
  • We founded Naveris on the belief that advances in molecular diagnostics will play a vital role in improving cancer outcomes.
  • Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution.

QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System

Retrieved on: 
Thursday, September 15, 2022

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.
  • The new assays support QIAGENs strategy of expanding the menu of tests available for use on the NeuMoDx 96 and 288 Molecular Systems.
  • The assay adds to the broad portfolio that QIAGEN offers to address all testing needs around monkeypox.
  • QIAGEN remains committed to responding to the COVID-19 endemic by preparing to launch a new multiple-target test: NeuMoDx FluA/FluB/RSV/SARS-CoV-2 Assay with a new dual-target SARS-CoV-2 design.